Point72 Europe London LLP Makes New Investment in Rezolute, Inc. (NASDAQ:RZLT)

Point72 Europe London LLP purchased a new position in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 146,932 shares of the company's stock, valued at approximately $720,000. Point72 Europe London LLP owned approximately 0.25% of Rezolute at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. raised its stake in shares of Rezolute by 699.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company's stock worth $12,377,000 after purchasing an additional 2,210,038 shares during the last quarter. Susquehanna International Group LLP boosted its holdings in Rezolute by 749.0% during the 4th quarter. Susquehanna International Group LLP now owns 893,601 shares of the company's stock valued at $4,379,000 after acquiring an additional 788,349 shares during the period. Walleye Capital LLC bought a new stake in shares of Rezolute in the fourth quarter worth about $2,408,000. Nantahala Capital Management LLC lifted its position in shares of Rezolute by 10.9% in the 4th quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock worth $14,004,000 after purchasing an additional 280,861 shares during the period. Finally, Integral Health Asset Management LLC raised its holdings in Rezolute by 100.0% in the fourth quarter. Integral Health Asset Management LLC now owns 500,000 shares of the company's stock worth $2,450,000 after purchasing an additional 250,000 shares in the last quarter. 82.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Rezolute news, CFO Daron Evans purchased 10,000 shares of the stock in a transaction on Wednesday, March 26th. The shares were purchased at an average price of $2.89 per share, with a total value of $28,900.00. Following the acquisition, the chief financial officer now directly owns 237,900 shares of the company's stock, valued at $687,531. This represents a 4.39% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Nevan C. Elam acquired 12,302 shares of the firm's stock in a transaction on Thursday, March 27th. The shares were purchased at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the purchase, the chief executive officer now directly owns 224,119 shares of the company's stock, valued at approximately $638,739.15. The trade was a 5.81% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 39,060 shares of company stock valued at $130,694 in the last quarter. Company insiders own 18.39% of the company's stock.

Rezolute Stock Up 6.4%

Shares of Rezolute stock traded up $0.23 on Monday, hitting $3.80. The company's stock had a trading volume of 866,358 shares, compared to its average volume of 630,588. The firm has a fifty day moving average price of $3.24 and a 200-day moving average price of $4.29. The company has a market capitalization of $230.03 million, a P/E ratio of -3.11 and a beta of 1.01. Rezolute, Inc. has a 52-week low of $2.22 and a 52-week high of $6.19.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). As a group, analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on RZLT shares. HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of Rezolute in a research note on Monday, April 28th. Wedbush restated an "outperform" rating and set a $12.00 target price on shares of Rezolute in a research report on Wednesday, May 14th. Guggenheim restated a "buy" rating on shares of Rezolute in a report on Monday, February 10th. JMP Securities upped their price objective on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research note on Thursday, February 13th. Finally, Craig Hallum upgraded Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Rezolute currently has a consensus rating of "Buy" and a consensus price target of $12.14.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.